Eliminate the exclusion criteria for prostate cancer clinical trial participation that requires a sicker, weaker patient who ultimately gets that way from the ADT.
Why is this important?
Every promising biotech cancer treatment currently requires prostate cancer patients to undergo and fail androgen deprivation therapy (ADT) to be part of any clinical trial. By the time this failure occurs, the patient is too sick and weak for the full benefit of the treatment to be realized. The ADT itself is a big part of the reason. Let these treatments be tried on their own merits.
